Compugen and Biosite Expand Dx-Development Alliance

Mar 07, 2007

NEW YORK (GenomeWeb News) — Biosite will have access to more of Compugen’s diagnostic and immunoassay biomarkers under a renewed and expanded partnership and licensing agreement, Compugen said today.

In June 2005 the companies penned an alliance to develop and commercialize immunoassay-based diagnostics for cardiovascular and oncology indications based on several of Compugen’s gene targets.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

New Framework Suggested

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

Penguins With Roving Eyes

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Funding Lost

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

This Week in Science

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

Main menu